Drug Profile
FF 10101 01
Alternative Names: FF 10101-01; FF-10101; FF-10101 succinateLatest Information Update: 21 May 2022
Price :
$50
*
At a glance
- Originator FUJIFILM Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Acute myeloid leukaemia presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 04 Jun 2021 Efficacy, adverse event and pharmacokinetics data from a phase I/IIa trial in Acute myeloid leukaemia presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
- 10 Dec 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2017)